Sage Therapeutics (SAGE) Competitors $5.27 -0.08 (-1.50%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SAGE vs. ARDX, SYRE, CALT, SPRY, ANIP, SNDX, RCKT, BCYC, AVDL, and COLLShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Ardelyx (ARDX), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), ANI Pharmaceuticals (ANIP), Syndax Pharmaceuticals (SNDX), Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Ardelyx Spyre Therapeutics Calliditas Therapeutics AB (publ) ARS Pharmaceuticals ANI Pharmaceuticals Syndax Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Collegium Pharmaceutical Ardelyx (NASDAQ:ARDX) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Does the media favor ARDX or SAGE? In the previous week, Sage Therapeutics had 1 more articles in the media than Ardelyx. MarketBeat recorded 7 mentions for Sage Therapeutics and 6 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.60 beat Sage Therapeutics' score of 0.17 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sage Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer ARDX or SAGE? Sage Therapeutics received 101 more outperform votes than Ardelyx when rated by MarketBeat users. However, 67.52% of users gave Ardelyx an outperform vote while only 65.39% of users gave Sage Therapeutics an outperform vote. CompanyUnderperformOutperformArdelyxOutperform Votes53067.52% Underperform Votes25532.48% Sage TherapeuticsOutperform Votes63165.39% Underperform Votes33434.61% Which has more risk & volatility, ARDX or SAGE? Ardelyx has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Is ARDX or SAGE more profitable? Ardelyx has a net margin of -28.82% compared to Sage Therapeutics' net margin of -317.29%. Ardelyx's return on equity of -46.60% beat Sage Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-28.82% -46.60% -21.49% Sage Therapeutics -317.29%-50.29%-45.48% Do analysts recommend ARDX or SAGE? Ardelyx presently has a consensus target price of $10.42, indicating a potential upside of 123.53%. Sage Therapeutics has a consensus target price of $11.53, indicating a potential upside of 118.77%. Given Ardelyx's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ardelyx is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Sage Therapeutics 2 Sell rating(s) 16 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, ARDX or SAGE? Ardelyx has higher revenue and earnings than Sage Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$251.85M4.38-$66.07M-$0.30-15.53Sage Therapeutics$106.40M3.03-$541.49M-$5.58-0.94 Do institutionals & insiders hold more shares of ARDX or SAGE? 58.9% of Ardelyx shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 5.9% of Ardelyx shares are held by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryArdelyx beats Sage Therapeutics on 14 of the 19 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$322.38M$6.87B$5.20B$9.31BDividend YieldN/A3.06%4.80%4.06%P/E Ratio-0.9410.75128.1117.53Price / Sales3.03287.461,260.62139.54Price / CashN/A56.6541.3637.95Price / Book0.405.394.894.92Net Income-$541.49M$152.04M$119.92M$225.78M7 Day Performance-10.53%-4.33%16.64%-1.56%1 Month Performance10.25%2.79%16.35%6.68%1 Year Performance-75.08%17.30%35.47%22.48% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics4.2242 of 5 stars$5.27-1.5%$11.53+118.8%-75.7%$322.38M$106.40M-0.94690Analyst ForecastARDXArdelyx3.8431 of 5 stars$5.39+3.3%$10.42+93.3%-21.2%$1.28B$251.85M-17.80267SYRESpyre Therapeutics1.9281 of 5 stars$24.65+2.2%$51.50+108.9%+63.0%$1.27B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)N/A$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals3.0568 of 5 stars$12.26+3.0%$24.00+95.8%+125.7%$1.19B$30,000.00-23.3390ANIPANI Pharmaceuticals4.8134 of 5 stars$56.07-0.9%$77.71+38.6%+5.5%$1.18B$555.46M-102.89642Short Interest ↓SNDXSyndax Pharmaceuticals3.9655 of 5 stars$13.73-1.4%$37.64+174.1%-34.4%$1.17B$16M-3.84110RCKTRocket Pharmaceuticals4.8614 of 5 stars$11.94-0.7%$51.00+327.1%-57.9%$1.09BN/A-4.37240Analyst RevisionBCYCBicycle Therapeutics3.5662 of 5 stars$15.46+11.9%$36.00+132.9%-13.5%$1.07B$26.98M-4.56240Analyst ForecastInsider TradeHigh Trading VolumeAVDLAvadel Pharmaceuticals2.7809 of 5 stars$10.93+5.2%$24.43+123.5%-23.3%$1.05B$138.16M-13.15154Short Interest ↑Positive NewsCOLLCollegium Pharmaceutical3.9712 of 5 stars$30.57+1.6%$42.60+39.4%+4.3%$985.88M$599.25M12.97210News CoveragePositive News Related Companies and Tools Related Companies Ardelyx Competitors Spyre Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors ARS Pharmaceuticals Competitors ANI Pharmaceuticals Competitors Syndax Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Bicycle Therapeutics Competitors Avadel Pharmaceuticals Competitors Collegium Pharmaceutical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SAGE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
